Navigation Links
MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support
Date:1/9/2012

NEW YORK, Jan. 9, 2012 /PRNewswire/ -- MolecularHealth, a clinico-molecular informatics company, today announced the commercialization and planned roll-out of two next generation product lines that translate patient-specific molecular and genomic data, clinical history and published scientific evidence into safer, more effective drug choices for patients.

"With the cost of producing genomic information falling drastically and clinical data becoming increasingly accessible, today's remaining challenge resides in the analysis and interpretation of this information," said Friedrich von Bohlen, Ph.D., MolecularHealth's chief executive officer. "MolecularHealth has developed and is commercializing solutions that translate clinical and molecular data into actionable information, delivering precision medicine – safe and efficacious treatment decisions."

The company announced the planned commercial launch of two product lines in drug safety and molecularly-guided treatment decision support. Molecular Analysis of Side Effects (MASE) combines adverse event information with clinico-molecular knowledge about drug activity within a patient.

The company's molecularly-guided treatment decision support solutions, which will initially be available for use in oncology, integrate molecular data – including whole genome sequences – with clinical information about a patient, translating these data into evidence-based treatment strategies for marketed and clinical stage therapies.

"When we founded SAP forty years ago, we believed that organizing previously disaggregate data and systems could make for more efficient, effective enterprise resource planning," said Dietmar Hopp, co-founder and former Chairman and CEO of SAP and, through dievini Hopp BioTech, the sole investor in MolecularHealth. "Today, I see a similar opportunity in the healthcare sector, and MolecularHealth is paving the way through the integration of clinical and molecular information."

The company also announced the initiation of its U.S. commercial operations in New York under the leadership of Jeffrey D. Marrazzo, former executive with Generation Health, a genetic benefit management company.

"In the next five years, most cancer patients will have molecular and genomic profiles of their tumors," said Mr. Marrazzo. "MolecularHealth's mature technology platform and clinical and research relationships, including with the M.D. Anderson Cancer Center, will enable us to help physicians and other stakeholders translate this information into the language of the user."

In the coming months, the company will make a series of announcements critical to the advancement of precision medicine.

About MolecularHealthMolecularHealth is on the forefront of precision medicine, applying a pioneering approach called clinico-molecular informatics to patient treatment. The company's knowledge-driven solutions translate patient-specific molecular and genomic data, clinical history and published scientific evidence into safer and more effective drug choices. For patients at risk of a serious adverse drug event, or for those awaiting their next course of cancer treatment, precision matters. MolecularHealth's offerings range from a next generation drug safety assessment tool that analyzes the molecular basis of adverse events to the first oncology decision support solution that transforms whole genome sequencing data into evidence-based treatment strategies.

The company maintains offices in Basel, Switzerland; Heidelberg, Germany; Houston and New York and is backed by the co-founder, former chairman and chief executive officer of SAP, Dietmar Hopp. MolecularHealth has successfully built upon its heritage as one of the leading software analysis providers for the Human Genome Project. In 2008, MolecularHealth entered into a ten-year strategic affiliation agreement with The University of Texas M.D. Anderson Cancer Center to pursue joint research projects in the area of molecular medicine for the discovery, validation and/or development of biomarkers, drug targets, combinatorial treatments, alternative medical uses, adverse drug reactions or modes of action of drugs and other compositions. The company is led by a team of seasoned entrepreneurs, scientists and technologists, including founding members of Generation Health, LION Bioscience, Model N Life Sciences and Xapien.  Media Contacts

Corporate ContactTony Russo, Ph.D.

Eric M. StoneMatt Middleman, M.D.

Vice President, Sales and MarketingRusso Partners

T: (713) 834-9990T: 212-845-4251

eric.stone@molecularhealth.comT: 212-845-4272

 tony.russo@russopartnersllc.com

 matt.middleman@russopartnersllc.com

 
'/>"/>

SOURCE MolecularHealth
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
2. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
3. Dr. Dello Russo Introduces the New EYE-Q Lasik
4. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
5. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
6. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
7. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
8. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
9. Siemens Introduces New Standard of Care for Breast Ultrasound
10. Perceptive Informatics Introduces Medical Imaging Methodology to Accelerate Development Decisions About Alzheimers Treatments
11. Quest Diagnostics Introduces First Commercial Laboratory Test for Identifying the H1N1 Swine Flu Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that ... Bisaro as Impax,s President and Chief Executive Officer ... 27, 2017. Mr. Bisaro will succeed J. Kevin ... Chief Executive Officer since December of 2016. ... experience, Mr. Bisaro, 56, is an accomplished global business ...
(Date:3/27/2017)... , March 27, 2017 Invivotek, LLC, a ... in vivo pharmacology contract research organization (CRO), ... to its newly expanded preclinical research facility in ... provides a cleaner, renewable energy source to reduce costs ... Completion of the Genesis Solar Farm follows Invivotek,s recent ...
(Date:3/24/2017)... 24, 2017  Zymo Research Corp., also ... Robotics, Inc., who designs, manufactures and distributes ... that teams Zymo Research,s DNA methylation detection ... extraction products with Hamilton,s high-throughput automation platforms. ... for microbiomics and RNA isolation for use ...
Breaking Medicine Technology:
(Date:3/27/2017)... Clearwater, FL (PRWEB) , ... March 27, 2017 ... ... accepts new patients for clear braces. People who want straight teeth without the ... Invisalign® in Clearwater, FL, without acquiring a referral. A custom-designed series ...
(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... 3.0 was transitioned to the OSEHRA popHealth Community in 2014. It ... Work Group and the Developer Open Source Project Group. OSEHRA Organizational Member Zato ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds upon ... industry standards and specifications such as ANSI, ISO and proven test methods used ...
(Date:3/27/2017)... ... 27, 2017 , ... Advantexe Learning Solutions , a ... a new research study, The Business Readiness Report. The report explores the correlation ... the actual success of achieving individual and company goals. , There are ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the ... including all stages, is more than 95%. Once the cancer spreads to other organs, ... 30%. To find out how to avoid this latter group, tune in to ...
Breaking Medicine News(10 mins):